<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04700709</url>
  </required_header>
  <id_info>
    <org_study_id>B110_01KT2002</org_study_id>
    <nct_id>NCT04700709</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Sirolimus Plus CNI Compared With MMF Plus CNI in ABO-i Kidney Transplant Recipients.</brief_title>
  <official_title>Evaluate the Efficacy and Safety of RaparoBell® Tablet Plus Calcineurin Inhibitors Compared With Mycophenolate Mofetil Plus Calcineurin Inhibitors in ABO Incompatible De Novo Living Kidney Transplant Recipients. [ART Study]</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of RaparoBell® Tablet Plus&#xD;
      Calcineurin Inhibitors Compared with Mycophenolate Mofetil Plus Calcineurin Inhibitors in ABO&#xD;
      incompatible De Novo Living Kidney Transplant Recipients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is Multi-center, Open-label, Randomized Controlled Phase 4 Study to Evaluate the&#xD;
      Efficacy and Safety of RaparoBell® Tablet Plus Calcineurin Inhibitors Compared with&#xD;
      Mycophenolate Mofetil Plus Calcineurin Inhibitors in ABO incompatible De Novo Living Kidney&#xD;
      Transplant Recipients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2021</start_date>
  <completion_date type="Anticipated">January 2025</completion_date>
  <primary_completion_date type="Anticipated">December 2024</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of composite efficacy failure</measure>
    <time_frame>Until 48 weeks after taking medicine</time_frame>
    <description>Composite efficacy failure include biopsy-confired acute rejection, graft loss, death, or follow-up failure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of composite efficacy failure</measure>
    <time_frame>Until 24 weeks after taking medicine</time_frame>
    <description>Composite efficacy failure include biopsy-confired acute rejection, graft loss, death, or follow-up failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of biopsy-confirmed acute rejection</measure>
    <time_frame>Until 24weeks and 48weeks after taking medicine</time_frame>
    <description>Banff Criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The pathological results and time of occurrence and method of treatment, result of the treatment of acute rejection confirmed by biopsy</measure>
    <time_frame>Until 24weeks and 48weeks after taking medicine</time_frame>
    <description>Banff Criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival rate</measure>
    <time_frame>Until 24weeks and 48weeks after taking medicine</time_frame>
    <description>transplanted organ and patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Function of Kidney</measure>
    <time_frame>Until 24weeks and 48weeks after taking medicine</time_frame>
    <description>eGFR using MDRD(Modification of Diet in Renal Disease) method</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of CMV, BKV infection</measure>
    <time_frame>Until 24weeks and 48weeks after taking medicine</time_frame>
    <description>Incidence of CMV, BKV infection</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">158</enrollment>
  <condition>Kidney Transplantation</condition>
  <arm_group>
    <arm_group_label>RaparoBell® Tablet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABO-i De novo Living Kidney transplant recipients will be randomized after Kidney transplant.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mycophenolate Mofetil Tablet/Capsule</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ABO-i De novo Living Kidney transplant recipients will be randomized after Kidney transplant.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sirolimus Tab.</intervention_name>
    <description>Orally, once-daily in the morning - The first dose is administered within maximum 6mg/day according to the investigator's judgement, check the blood concentration of Sirolimus at each visit and adjust the dose to acheive the blood concentration maintaining at 3~8ng/ml.</description>
    <arm_group_label>RaparoBell® Tablet</arm_group_label>
    <other_name>RaparoBell® Tab.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate Mofetil Cap./Tab.</intervention_name>
    <description>Up to 1g BID(total 2g daily), PO</description>
    <arm_group_label>Mycophenolate Mofetil Tablet/Capsule</arm_group_label>
    <other_name>Myrept® Cap./Tab.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        [Time of Screening]&#xD;
&#xD;
          1. Patients who plan to be transplanted ABO incompatible living donor kidney or not past&#xD;
             35 days after kidney transplantation&#xD;
&#xD;
          2. More than the age of 19 years old&#xD;
&#xD;
          3. Agreement with written informed consent&#xD;
&#xD;
        [Time of Randomization]&#xD;
&#xD;
          1. Patients who have transplanted Kidney within 4 weeks(25 days to 35 days)&#xD;
&#xD;
          2. Patients who take CNI plus MMF after kidney transplantation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        [Time of Screening]&#xD;
&#xD;
          1. Patients who have transplanted non-kidney organs or have plan to be transplanted&#xD;
             non-kidney organs&#xD;
&#xD;
          2. PRA &gt; 50% before desenitization or positive results of DSA&#xD;
&#xD;
          3. Receive a kidney from a related donor who showed HLA identical&#xD;
&#xD;
          4. Positive in serology test(HIV, HBsAg, HCV) in recipients and/or donor&#xD;
&#xD;
          5. Allergic/hypersensitivity reaction in the history of Investigational drugs or&#xD;
             additives&#xD;
&#xD;
          6. Women who are pregnant or breast feeding or not agree to the proper use of&#xD;
             contraception during the trial&#xD;
&#xD;
          7. Patient has conversation impairment because of mental illness within 6months&#xD;
&#xD;
          8. Participated in other trial within 4 weeks&#xD;
&#xD;
          9. In investigator's judgement&#xD;
&#xD;
        [Time of Randomization]&#xD;
&#xD;
          1. Patients with acute rejection who have been clinically treated after kidney&#xD;
             transplantation&#xD;
&#xD;
          2. At the time of Randomization&#xD;
&#xD;
               -  Treatment with active liver disease or Liver function test(T-bilirubin, AST,&#xD;
                  ALT)is over 3 times than upper normal limit&#xD;
&#xD;
               -  WBC&lt; 2,500/mm^3, or platelet &lt; 75,000/mm^3, or ANC &lt; 1,300/mm^3&#xD;
&#xD;
          3. Patients who had plasmapheresis within 1 week&#xD;
&#xD;
          4. Patents who had a record of taking mTOR inhibitor before&#xD;
&#xD;
          5. In investigator's judgement&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyu Ha Huh, M.D, Ph.D</last_name>
    <role>Study Chair</role>
    <affiliation>Severance Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kyu Ha Huh, M.D, Ph.D</last_name>
    <phone>+82-2-2228-2138</phone>
    <email>KHHUH@yuhs.ac</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jung A Lee</last_name>
    <phone>+82-2-2194-0403</phone>
    <email>junaa82@ckdpharm.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 6, 2021</study_first_submitted>
  <study_first_submitted_qc>January 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 8, 2021</study_first_posted>
  <last_update_submitted>January 6, 2021</last_update_submitted>
  <last_update_submitted_qc>January 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Kidney Transplantation</keyword>
  <keyword>ABO incompatible</keyword>
  <keyword>Sirolimus</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

